Frazier Life Sciences News and Activities

Frazier Life Sciences is owned by Frazier Healthcare Partners.

Frazier Healthcare Partners has 9 subsidiaries including AirNexis Therapeutics, Altruix and Comprehensive Pharmacy Services.

They are in:

• Healthcare30%
• Fund20%
• Other50%

Acquisition, funding and merger involving Frazier Healthcare Partners.

• Frazier Healthcare Partners has acquired Altruix (posted on May 29 2026).

View the org chart displaying its 43 main executives

Most searched biographies at Frazier Life Sciences

• Albert Cha, Managing Partner
• Patrick Heron, Managing Partner
• James Topper, Managing Partner

Popular executive movements at Frazier Life Sciences

• Mansi Shinde has joined the company as Vice President of Company Creation  (posted on March 22 2026).
• Kiah Williams, who was Senior Associate, is promoted to Vice President  (posted on January 13 2026).
• Angel Martin, who was Senior Associate, is promoted to Vice President  (posted on January 13 2026).

Click here to view some more movements at Frazier Life Sciences

Create your alert
to follow the executive moves at Frazier Life Sciences.

Frazier Healthcare Partners has 1,642 competitors including Griffin Gaming Partners (United States (USA)), BlackRock (United States (USA)) and KKR (United States (USA)).

Popular M&A news in Fund

• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (posted on June 3 2026).
• Prime Capital Financial has acquired Access Capital Partners (posted on June 2 2026).
• Frazier Healthcare Partners has acquired Altruix (posted on May 29 2026).

Popular contacts in Fund

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer at Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director at Vanguard
• Scott Nuttall - Co-Chief Executive Officer and Director at KKR

Learn more about the Fund industry

Press releases by Frazier Life Sciences

• GSK enters agreement to acquire 35Pharma Inc. | GSK
• Page not found
• Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer
• Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
• Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
• Frazier Life Sciences Appoints Charles Fuchs as Senior Advisor
• Frazier Life Sciences Announces Multiple Promotions to Key Senior Level Positions
• Tubulis raises €308M to advance ADC development · Tubulis News
• Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
• KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema | KalVista Pharmaceuticals
• View more press releases Close

Social media about Frazier Life Sciences

• Frazier Life Sciences on Wikipedia, Google News & Yahoo Finance
• Frazier Life Sciences on LinkedIn, X (Twitter) & YouTube